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Abstract
Interleukin-17F (IL-17F), produced by Th17 cells and other immune cells, is a member of IL-17 cytokine family with highest
homology to IL-17A. IL-17F has been shown to have multiple functions in inflammatory responses. While IL-17A plays
important roles in cancer development, the function of IL-17F in tumorigenesis has not yet been elucidated. In the current
study, we found that IL-17F is expressed in normal human colonic epithelial cells, but this expression is greatly decreased in
colon cancer tissues. To examine the roles of IL-17F in colon cancer, we have used IL-17F over-expressing colon cancer cell
lines and IL-17F-deficient mice. Our data showed decreased tumor growth of IL-17F-transfected HCT116 cells comparing to
mock transfectants when transplanted in nude mice. Conversely, there were increased colonic tumor numbers and tumor
areas in Il-17f
2/2 mice than those from wild-type controls after colon cancer induction. These results indicate that IL-17F
plays an inhibitory role in colon tumorigenesis in vivo. In IL-17F over-expressing tumors, there was no significant change in
leukocyte infiltration; instead, we found decreased VEGF levels and CD31
+ cells. While the VEGF levels were increased in the
colon tissues of Il-17f
2/2 mice with colon cancer. Together, our findings demonstrate a protective role for IL-17F in colon
cancer development, possibly via inhibiting tumor angiogenesis.
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Introduction
Interleukin-17F (IL-17F) is a pro-inflammatory cytokine pro-
duced by activated T cells and other types of immune cells [1,2].
IL-17F together with 5 other cytokines, including IL-17A,
constitute the IL-17 cytokine family [3,4]. The major source for
IL-17A is a new subset of T helper cells, TH17 cells, as well as cdT
cells, both of which also produce IL-17F [5]. IL-17F and IL-17A
share the strongest amino acid homology and their coding genes
locate adjacent to each other on the chromosome [6]. IL-17F
could form homodimers or heterodimers with IL-17A in both
human and mice [7,8]. Similar to IL-17A, IL-17F induces the
production of many pro-inflammatory cytokines (IL-6/GM-CSF)
and chemokines (CXCL1/2/5) in different cell types, as well as
enhances granulopoiesis and neutrophil recruitment [9].
IL-17F and IL-17A could utilize the same receptor complexes
consisting of IL-17RA and IL-17RC, but different binding
affinities and differential expression patterns of IL-17RA and IL-
17RC may contribute to overlapping but differential functions of
IL-17F versus IL-17A in vivo [10]. IL-17F and IL-17A have been
reported associated with the pathogenesis of multiple inflamma-
tory diseases, such as asthma and arthritis [11]. In intestinal
inflammation, both IL-17F and IL-17A showed up-regulated
expression [12,13]. However, Il-17f
2/2 mice were resistant to
dextran sulfate sodium (DSS)-induced colitis [14], while Il-17a
deficiency exacerbated this disease [14,15]. The basis for this
difference is unclear but IL-17F was reported to be expressed by
non-lymphoid cells that do not express IL-17A, such as mouse
colonic epithelial cells [16].
IL-17A has been found in various tumors and appears to have
both pro-tumor and anti-tumor roles depending on the type of
tumors and also the existence of host lymphoid system [17]. Some
studies showed IL-17A supports tumor growth by facilitating
angiogenesis of cervical cancer and lung cancer [18,19]. In
contrast, other reports suggested IL-17A promotes T cell-mediated
tumor rejection in fibrosarcoma, hematopoietic immunogenic
tumor and lung melanoma [20,21,22]. In colorectal cancer
samples, clinical research showed increased IL-17A expression
[23,24]. IL-17A deficiency caused significantly reduced intestinal
tumorigenesis in Apc
Min/+ mice [25] and IL-17A blocking
antibody could inhibit enterotoxigenic bacteroides fragilis
(ETBF)-induced colon carcinogenesis [26]. Therefore, IL-17A
may play a pathogenic role in colon cancer. Despite this
knowledge, the function of IL-17F in tumorigenesis has been
poorly studied.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34959To address the function of IL-17F in colon cancer, we evaluated
IL-17F levels in the human colon cancer tissues and investigated
the tumorigenesis by using IL-17F-transfected colon cancer cell
lines in nude mice and a chemically-induced colon cancer model
in Il-17f
2/2 mice. Our results show that IL-17F plays an
inhibitory role in colon tumorigenesis in vivo.
Results
Decreased IL-17F expression associated with human
colon cancer
As a first step to determine the function of IL-17F in colon
cancer, we analyzed colonic samples from colon cancer patients
and found lower mRNA levels of IL-17F in cancer tissues when
compared with corresponding normal tissues in the distal margin
of the same surgical resection (Figure 1A). Characteristics of the
patients are shown (Table S1). Consistent with the mRNA data,
we also found lower protein levels of IL-17F in colonic cancer
tissues than corresponding normal tissues (Figure 1B). At the same
time, we found the mRNA and protein levels of IL-17A showed no
significant difference (Figure 1A–B). Interestingly, similar to
previously reported expression in mouse colonic epithelial cells,
immuno-staining showed that IL-17F was expressed in normal
colonic epithelial cells; however, this expression was substantially
reduced in malignant epithelial cells (Figure 1C). These data
indicated that human IL-17F is expressed in normal colonic
epithelial cells but this expression is down-regulated during
tumorigenesis, which suggests a role for IL-17F in colonic
epithelial tumorigenesis.
Over-expression of IL-17F inhibits colon tumorigenesis in
vivo
To investigate the role of IL-17F in tumorigenesis, we stably
transfected colon cancer cell line HCT116 cells with IL-17F cDNA
and empty vector as control (mock transfectant). Western blot
analysis of the cellular proteins (Figure 2A) and ELISA analysis of
cultural supernatants (Figure 2B) both showed abundant IL-17F
expression in the IL-17F-transfected monoclonal HCT116 cells,
while undetectable IL-17F in mock-transfected and wild-type
HCT116 cells. Real-time RT-PCR data also showed the mRNA
expression of IL-17F was remarkably increased in IL-17F-
transfected HCT116 cells (Figure 2C). Notably, the mRNA levels
of IL-6 and TNFa were also significantly elevated in the IL-17F-
transfected group, while those of IL-17A were slightly increased
(Figure 2C).
We then compared the cell apoptosis, cell cycle and cell growth
of the IL-17F-transfected, mock-transfected and wild-type
HCT116 cells in vitro. FACS analysis showed no significant
difference in cell apoptosis and cell cycle among the three groups
under normal culture condition (Figure S1A). Slightly increased
G0/1 ratio of IL-17F-transfected HCT116 cells after serum
starvation for 24 h (Figure S1B). MTT experiments showed
identical cell growth (Figure S1C). Soft agar assay showed similar
clone formation ability among the three groups (Data not shown).
These results revealed that IL-17F may not directly affect
apoptosis and proliferation of colon cancer cells in vitro.
However, in vivo, IL-17F-transfected HCT116 cells grew
significantly slower than wild-type cells when transplanted in
nude mice (Figure 2D–F). At 3 weeks after transplantation, the
Figure 1. Decreased IL-17F expression associated with human
colon cancer. (A) Real-time RT-PCR analysis revealed decreased mRNA
levels of IL-17F in cancer samples comparing to corresponding normal
mucosa, totally 40 pairs of colon samples. (B) Western blot analysis
revealed decreased IL-17F expression in cancer samples. Depicted are 4
individual pairs of colon samples. (C) Immunohistochemistry staining of
human colon sections using anti-IL-17F antibody. Bar=50 mm.
*, P,0.05.
doi:10.1371/journal.pone.0034959.g001
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three different IL-17F-transfected tumors, and 0.062 g in wild-
type tumors (Figure 2E). During the tumor growth, the mean
tumor volumes were increased from 10 at week 1 to 92 mm
3 at
week 3 in IL-17F-transfected clone1 tumors, from 9 to 81 mm
3 in
clone2, and from 17 to 120 mm
3 in clone3, while 14 to 153 mm
3
in wild-type tumors during the same period of time (Figure 2F). IL-
17F appears to inhibit the tumor growth much more pronounced-
ly after an initial period in nude mice, suggesting that IL-17F did
not affect the initial stage of tumor development but rather
suppressed its progression.
Enhanced colon tumor development in IL-17F-deficient
mice
In wild-type mice, IL-17F was mainly produced by colon
epithelial cells, while IL-17A was undetectable in colon epithelial
cells (Figure 3A). To further evaluate the role of IL-17F in
tumorigenesis, we used AOM-DSS induced inflammation-associ-
ated colon cancer model in Il-17f
2/2, Il-17a
2/2 and wild-type
mice. Colons from Il-17f
2/2 mice contained significantly more
tumor numbers and tumor areas relative to those from wild-type
controls (Figure 3B–D), while colons from Il-17a
2/2 mice
exhibited much fewer tumor polyps and less tumor areas
compared with those from wild-type mice. The tumor polyps
were sectioned and verified by H&E staining (Figure 3E). The
enhanced tumor formation in Il-17f
2/2 mice was consistent with
inhibited tumor growth by IL-17F over-expression, together
revealed an inhibitory role for IL-17F in colon tumorigenesis in
vivo.
IL-17F negatively regulates angiogenesis in vivo
To find out the possible reason for IL-17F-inhibited tumori-
genesis in vivo, we analyzed cell frequencies of several immune cell
subsets. In HCT116 transplanted tumors, similar cell populations
based upon CD11b, Gr-1 and CD49b stainings were observed in
IL-17F- and mock-transfected tumors (Figure S2A). In AOM-DSS
treated Il-17f
2/2, Il-17a
2/2 and WT mice, comparable cell
frequencies of IFNc
+CD4
+, IFNc
+CD8
+, and NK1.1
+ cells in
mesenteric lymph nodes (Figure S2B). Collectively, we found no
major change in the immune cell subsets by IL-17F, suggesting
anti-tumor immunity may not significantly contribute to the
reduced colon tumorigenesis in our study.
The inhibition of IL-17F on the endothelial angiogenesis [1]
prompted us to examine the tumor angiogenesis. In the nude mice
model, analysis of the tumor sections showed weaker VEGF
Figure 2. Over-expression of IL-17F inhibits colon tumorigenesis in vivo. (A) Western blot analysis of protein lysates from IL-17F-transfected
(Clone1, 2, 3), mock-transfected (Neo) and wild-type (WT) HCT116 cells. (B) ELISA analysis of IL-17F in supernatants of the cultured cells. (C) Real-time
RT-PCR analysis of the cells. (D) Tumor images and (E) tumor weights on Week 3 after transplantation of IL-17F- or wild-type HCT116 cells into nude
mice. (F) Tumor sizes during three weeks after the transplantation (n=10). *, P,0.05. **, P,0.001.
doi:10.1371/journal.pone.0034959.g002
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HCT116 tumors (Figure 4A). ELISA measurements also showed
lower VEGF levels in HCT116-IL-17F tumors (Figure 4B). In
FACS analysis of tumors, fewer CD31
+ cells existed in HCT116-
IL-17F (8.960.7%) than HCT116-Neo (14.861.5%) tumors
(Figure 4C). These data suggested inhibited tumor angiogenesis
by IL-17F in vivo. In the AOM-DSS colon cancer model, there
were more vascular tubes in the basal layer of Il-17f2/2 mice
than in that of wild-type mice, while there were very few small
vascular tubes in that of Il-17a2/2 mice (Figure 3E). Analysis of
the tumor sections showed stronger VEGF staining in Il-17f2/2
mice than in wild-type mice (Figure 4D). The mRNA levels of Vegf
were also increased in the colon tissues of AOM-DSS treated Il-
17f2/2 mice (Figure 4E), while those of Il-17a were decreased
and Tnfa were not significantly changed.
Figure 3. Enhanced colon tumor development in IL-17F-deficient mice. (A) Immunohistochemistry stainings of colon sections from WT mice
using anti-IL-17F and IL-17A antibodies. Bar=10 mm. (B) Tumor images, (C) Tumor numbers and (D) Tumor areas from the colons of AOM-DSS treated
WT, Il-17a
2/2 and Il-17f
2/2 mice. Data shown are a combination of 2 independent experiments (WT, n=8, Il-17a
2/2, n=6, and Il-17f
2/2, n=8).
*, P,0.05. **, P,0.005. (E) H&E stainings of the tumor sections. Arrows pointed out vascular tubes in the basal layer (At least 3 mice from each group
were analyzed and representative picture were shown). Bar=100 mm.
doi:10.1371/journal.pone.0034959.g003
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34959Figure 4. IL-17F inhibits angiogenesis in vivo. (A) VEGF staining of transplanted tumors of IL-17F- and mock-transfected HCT116 cells. (B) ELISA
analysis of VEGF and IL-17F levels in homogenized tumors from 3 mice (No5, No8, and No12). (C) FACS analysis of CD31 in transplanted tumors after
gating on PI negative cells. A representative data was shown (n=12). (D) VEGF stainings of colon samples from AOM-DSS treated WT and Il-17f
2/2
mice. (E) Real-time RT-PCR analysis of the colon samples from AOM-DSS treated WT and Il-17f
2/2 mice (n=4–8). Data shown are a combination of 2
independent experiments. *, P,0.05.
doi:10.1371/journal.pone.0034959.g004
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(400621 pg/ml) in the cultural supernatants of the IL-17F-
transfected, mock-transfected and wild-type HCT116 cells (Figure
S3A). Conditional medium (1/2) from these cells were used to
treat HUVEC cells for 24 h, but the cell growth and cell cycle of
HUVEC cells showed no change (Figure S3B–C). These results
implied that IL-17F may indirectly regulate angiogenesis in vivo.
Discussion
IL-17A has been found with various functions in different
tumors and may play a pathogenic role in colon cancer
development. However, the function of IL-17F is poorly
understood. In this study, by using both over-expression and
deletion of IL-17F in colon cancer models, we suggest IL-17F has
a protective role in colon tumorigenesis. We found that IL-17F is
expressed in normal human colonic epithelial cells, which is down-
regulated in colon cancer tissues. Besides, over-expression of IL-
17F inhibited the in vivo growth of HCT116 cells, an epithelial cell
line derived from human colon carcinoma. Therefore, our findings
for the first time indicate that IL-17F plays an important role in
the tumorigenesis of human colonic epithelial cells.
We found IL-17F inhibited colon tumorigenesis in vivo, which is
opposite from IL-17A function. Our data showed suppressed colon
tumor development of Il-17a
2/2 mice in AOM-DSS model,
which was consistent with the observations in APC
min/+
background [25]. It was also reported that over-expression IL-
17A in colon cancer cell lines promoted tumor growth in mice
[27]. Meanwhile, enhanced tumor formation of Il-17f
2/2 mice in
AOM-DSS model and reduced tumor growth of IL-17F over-
expression cells in nude mice were found in our study. The
contrasting effects of IL-17F and IL-17A have also been observed
in intestinal inflammation: IL-17F deficiency reduced while IL-
17A deficiency exacerbated DSS induced colitis [14,15]. Consid-
ering the complex connections between chronic inflammation and
tumorigenesis [28,29], the two similar but different cytokines
possibly form a balance in regulating colonic homeostasis. On the
other hand, IL-17a showed increased levels in IL-17F over-
expression HCT116 cells and decreased levels in the colon tissues
of AOM-DSS treated il-17f2/2 mice, suggesting a compensatory
regulation of IL-17F and IL-17A gene expressions in colon cancer.
Further studies are needed, and our study represents a first step
toward a better understanding the roles of IL-17F and IL-17A in
colonic tumorigenesis.
What’s the mechanism underlying the inhibition of colon
tumorigenesis by IL-17F? Since IL-17F- and mock-transfected
HCT116 cells exhibited similar in vitro proliferation kinetics, it is
unlikely that IL-17F directly affects in vivo proliferation of the
transplanted colonic tumors. Our previous work showed Th17
cells promote the activation of tumor specific CD8
+ T cells [22].
Since IL-17F is an important effecter of Th17 cells, the mechanism
involved in our current study is probably a host-depended tumor
growth inhibiting effects induced by IL-17F. However, we found
no change in leukocyte infiltration in tumors over-expressing IL-
17F despite the elevated levels of IL-6 and TNFa in vitro, and
unaltered cytotoxic immune cell frequencies in mesenteric lymph
nodes of colon tumor bearing Il-17f
2/2 mice. These results were
supported by the report that IL-17F did not affect the migration of
mature leukocytes in vitro [1].
In the meantime, we found IL-17F-over-expressing tumors had
decreased VEGF levels and CD31
+ cells, which suggested an
inhibited angiogenesis. IL-17F suppressed the progression of
transplanted tumor but not the initial development. This
phenotype is consistent with possible decreased angiogenesis, since
angiogenesis is a critical process for the sustained growth of solid
tumors. On the other hand, we found more vascular tubes in the
basal layer and increased VEGF levels in the colon tumor of Il-
17f2/2 mice. But it’s difficult to determine whether the decreased
angiogenesis is a cause or effect in primary tumors. Together, our
findings suggest that IL-17F suppresses colon cancer development
possibly via inhibiting tumor angiogenesis. In support of our
results, over-expression of IL-17F in human hepatocellular
carcinoma cells was reported with a decrease in tumor size and
microvessel density in nude mice [30]. However, we found that IL-
17F had no direct effect on the in vitro proliferation of vascular
endothelial cells (HUVECs) and decreased VEGF production was
only found in vivo in HCT116 tumor but not in vitro. Similarly, IL-
17A promoted tumor angiogenesis in vivo but failed to exhibit any
mitogenic activity for HUVECs in vitro; it regulated the production
of VEGF depending on cell types in vitro [27]. This differential
regulation in vivo and in vitro is unclear at this point. One possible
explanation is that another cell in the tumor microenvironments
was regulated by IL-17F/IL-17A in production of VEGF. On the
other hand, we found IL-17F dramatically increased TNFa
expression in HCT116 cells, and consistent high level of TNFa
was reported acted as anti-angiogenic conditions [31]. Together,
our data suggest an involvement of IL-17F in the tumor
angiogenesis.
In summary, we found that IL-17F is expressed in human
colonic epithelial cells and inhibits colon tumorigenesis in vivo,
possibly by inhibiting angiogenesis. Future study of the mechanism
will provide a unique and promising therapeutic approach for
colon cancer.
Materials and Methods
Clinical sample
Colon cancer tissues and distal normal colonic mucosa were
obtained from 40 patients undergoing surgical resection for colon
cancer in the Department of Oncology, Zhongnan Hospital of
Wuhan University. Cancer tissues and normal tissues were
dissected immediately and snap-frozen in liquid nitrogen. All
patients signed informed consents for scientific analysis and this
study was approved by the Ethical Committee of Wuhan
University.
Animal studies
4–6 week old female BALB/c nude mice were used for
transplantation experiments with cancer cells. Il-17f
2/2 [14], Il-
17a
2/2 and wild-type C57BL/6 mice were used for inducing
colon cancer by AOM-DSS. All mice were housed in pathogen-
free facilities on a 12-h light-dark cycle. All protocols and
procedures in this study were approved by the Ethics Committee
of Wuhan University (Permit Number: 2010-10007) and M.D.
Anderson Cancer Center (Permit Number: 05-05-04233).
Cell Culture
The HCT116 human colorectal cancer cell line and human
umbilical vein endothelial cells (HUVEC) were obtained from the
American Type Culture Collection and cultured in DMEM
(GIBCO) supplemented with 10%FCS. Human IL-17F cDNA was
kindly offered by Melissa A.Starovasnik, Genentech.Inc [32] and
subcloned into pcDNA3.1vector. HCT116 cells were electropo-
rated with BglII linearized IL-17F cDNA construct or pcDNA3.1
vector using Bio-Rad Gene Pulser at 250 V 960 uF. At 48 h after
electroporation, transfectants were selected in culture medium
supplemented with 800 ug/ml G418 (Merck). G418-resistant
monoclones were picked and expanded in the selection medium.
IL-17F Function in Colon Cancer
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10
6 cells were suspended in 200 ul PBS and injected
subcutaneously into the lower back of nude mice. IL-17F-
transfected HCT116 cells were injected into the right side with
vector-transfected HCT116 cells into the left side. Tumor volumes
were measured in cubic millimeters with vernier caliper and
calculated by the formula tumor size=ab
2/2. The a is the larger
and b is the smaller of the two dimensions. At 3 weeks after
transplantation, tumors were separated into two equal parts: one
part was used for FACS analysis, the other fixed in 4%
paraformaldehyde or snap-frozen in liquid nitrogen.
AOM-DSS induced colon cancer
Il-17f
2/2, Il-17a
2/2 and WT mice were injected intraperitone-
ally with a initial dose (10 mg/kg AOM in sterile distilled water) of
genotoxic colon carcinogen AOM followed by 3 cycles of orally fed
DSS (2% in drink water) for 1 week and regular drinkingwater for 2
weeks as described before [33]. After 9 weeks, colons were collected
from the resulting mice and fixed in 4% paraformaldehyde.
Numbers and areas of tumor polyps in the colons were analyzed.
Mesenteric lymph nodes were collected for FACS analysis.
Histochemistry
Tumor biopsies were fixed in 4% paraformaldehyde. 5 mm thick
paraffin sections were incubated with primary antibodies. Mouse
anti-human IL-17F was obtained from R&D, mouse anti-human
IL-17A was from ebioscience and rabbit anti-human VEGF was
from Santa Cruz Biotechnology. Sections incubated with isotype-
matched antibodies were used as negative control. The secondary
antibodies were HRP conjugated goat anti-mouse or rabbit IgG.
Nuclei were detected by hematoxylin counter-staining.
FACS analysis of tissue cells
Fresh transplanted tumor biopsies were scissored into small
pieces, and separated into single cells using collagenase IV and cell
dissociation solution (Sigma). Mesenteric lymph nodes were
minced and cells were washed using PBS. Single cells were
collected and stained. Different fluorescence conjugated anti-
mouse CD11b, Gr-1, CD49b, CD31, CD4, CD8, IFNc, NK1.1
were from ebioscience.
ELISA
Cells with the same beginning numbers were cultured in the
same volume of medium and the supernatant were collected when
cells reached 90% confluence. Tumor tissues were homogenized in
PBS and the supernatant were collected after centrifugation.
Human IL-17F or VEGF concentrations in the supernatants were
determined using Elisa kits as recommended by the assay
manufacturer. At the same time, protein concentrations in the
supernatants were determined by BCA protein assay kit (pierce).
Quantitative RT-PCR
RNA were extracted using Trizol method and reverse
transcripted to cDNA using RT Kit (Invitrogen). Quantitative
PCR analyses were performed on Bio-Rad CFX96 System using
the SYBR Green PCR Master Mix (Takara). The relative RNA
level of each gene was normalized against b-ACTIN. Primers used
for human genes: IL-17F:5 9-ACC CCT CGG AAG TTG TAC-
39 and 59-CAG TCA CCA GCA CCT TC-39. IL-17A:5 9- GAA
GTT CTG GGA GGA GAC ATT G-39 and 59- GGA GTG
TTG CTT GAG GAA GAG-39. IL-6:5 9- ACA ACT CAT CTC
ATT CTG C-39 and 59- GTG TCC TAA CGC TCA TAC-39.
TNFa:5 9- GGT ATG AGC CCA TCT ATC TG-39 and 59- GCA
ATG ATC CCA AAG TAG AC-39. TGFb:5 9-CCC ACA ACG
AAA TCT ATG AC-39 and 59-TGA GGT ATC GCC AGG
AAT-39. b-ACTIN:5 9-GCG TGA CAT TAA GGA GAA G-39
and 59-GAA GGA AGG CTG GAA GAG-39. Primers used for
mouse genes: Il-17a: 59-CTC CAG AAG GCC CTC AGA CTA
C-39 and 59-GGG TCT TCA TTG CGG TGG-39. Tnfa: 59-GAC
CCT CAC ACT CAG ATC ATC-39 and 59-CGC TGG CTC
AGC CAC TC-39. Vegf: 59-TCC CAG GCT GCA CCC ACG
ACA G-39 and 59-TGA CGT GGG CAC GCA CTC CAG G-39.
b-actin: 59-TGA AGA TCA AGA TCA TTG CTC CTC-39 and
59-CCT GCT TGC TGA TCC ACA TC-39.
Western blot analysis
40–60 mg protein were loaded on SDS-12% PAGE Gel. Blots
were probed with mouse anti-human IL-17F or IL-17A, and anti-
human b-ACTIN as loading control. Signal intensities in the blots
were measured by Quantity One software and transformed to the
bar graphs.
Statistical analysis
All values are expressed as mean 6 standard error of the mean.
Differences were analyzed using student’s t-test and p,=0.05
considered statically significant.
Supporting Information
Figure S1 IL-17F does not affect cell apoptosis, cell cycle
and cell growth in vitro. FACS analysis of IL-17F-transfected,
mock-transfected and wild-type HCT116 cells cultured in
10%FBS medium (A) or 0.1%FBS medium (B). (C) MTT analysis
of IL-17F-transfected, mock-transfected and wild-type HCT116
cells.
(TIF)
Figure S2 IL-17F does not change immune cell subsets
in vivo. (A) FACS analysis of CD11b, Gr-1, and CD49b in
transplanted tumors of IL-17F- and mock-transfected HCT116
cells. (B) IFNc
+CD4
+, IFNc
+CD8
+ and NK1.1
+ cell frequencies in
mesenteric lymph node cells from AOM-DSS treated WT, Il-
17a
2/2 and Il-17f
2/2 mice.
(TIF)
Figure S3 IL-17F does not influence cell growth and cell
cycle of HUVEC cells in vitro. (A) Elisa analysis of VEGF
levels in supernatants of IL-17F-transfected, mock-transfected and
wild-type HCT116 cells. MTT analysis (B) and FACS analysis (C)
of HUVEC cells cultured in conditioned medium (from IL-17F-
transfected, mock-transfected or wild-type HCT116 cells) or
normal medium.
(TIF)
Table S1 Clinical and pathological characteristics of
patients with colorectal cancer.
(DOC)
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